| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2019 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CYTOKINETICS INC | 3 | Q2 2024 | 12.9% |
| 89BIO INC | 3 | Q2 2024 | 8.1% |
| BRIDGEBIO PHARMA INC | 3 | Q2 2024 | 7.2% |
| NKARTA INC | 3 | Q2 2024 | 8.5% |
| SAVARA INC | 3 | Q2 2024 | 6.8% |
| FATE THERAPEUTICS INC | 3 | Q2 2024 | 4.5% |
| KEROS THERAPEUTICS INC | 3 | Q2 2024 | 4.3% |
| MARINUS PHARMACEUTICALS INC | 3 | Q2 2024 | 3.6% |
| ALLOGENE THERAPEUTICS INC | 3 | Q2 2024 | 2.0% |
| SPRUCE BIOSCIENCES INC | 3 | Q2 2024 | 0.2% |
View SUPERSTRING CAPITAL MANAGEMENT LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
View SUPERSTRING CAPITAL MANAGEMENT LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.